

THE PATENT OFFICE IS HEREBY REQUESTED TO ACKNOWLEDGE RECEIPT
OF THE FOLLOWING DOCUMENTS BY DATE STAMPING AND RETURNING
THIS POST CARD

Serial No: 08/182,183 Applicant: Lin et al.
Filed: May 23, 1994 Examiner: Marianne P. Allen Art Unit: 1818
Title: Glial Cell Line-Derived Neurotrophic Factor

1 pg Amendment Transmittal + 1 copy
10 pgs Response and Amendment
2 pgs Declaration



S:225E
DRC/khh


Via First Class Mail

September 11, 1997

Amgen Inc.
1840 DeHavilland Drive
Thousand Oaks, CA 91320-1789

AMGEN

Assistant Commissioner for Patents
Washington DC 20231


FEE AUTHORIZATION / AMENDMENT TRANSMITTAL LETTER				Attorney's Docket No: SYNE-225E		
Serial No. 08/182,183	Filing Date May 23, 1994	Examiner Marianne P. Allen	Group Art Unit 1818			
In Re Application of Lin, et al.						
For Glial Cell Line-Derived Neurotrophic Factor						
TO THE ASSISTANT COMMISSIONER FOR PATENTS:						
<input checked="" type="checkbox"/> Applicants petition for the following extension of time under 37 C.F.R. 1.136(a): <div style="margin-left: 20px;"> <input type="checkbox"/> One month of original due date (\$110.00) <input type="checkbox"/> Two months of original due date (\$390.00) <input checked="" type="checkbox"/> Three months of original due date (\$930.00) <input type="checkbox"/> Four months of original due date (\$1,470.00) </div>						
<input checked="" type="checkbox"/> A response in connection with the matter for which this extension is requested: <div style="margin-left: 20px;"> <input checked="" type="checkbox"/> is filed herewith. <input type="checkbox"/> has been filed. <input type="checkbox"/> The response is the filing of a continuation application having an express abandonment conditioned on the granting of a filing date to the continuing application. </div>						
<input type="checkbox"/> The accompanying papers include amended claims for which no additional fee is required.						
<input checked="" type="checkbox"/> The accompanying papers include amended claims the fee for which has been calculated as follows:						
CLAIMS AS AMENDED						
(1)	(2) Claims remaining after amendment	(3)	(4) Highest number previously paid for	(5) No. of extra claims present	(6) Rate	(7) Additional Fee
Total Claims	122	Minus	74 =	48	x \$22	= \$1,056.00
Indep. Claims	10	Minus	15 =		x \$80	=
First Occurrence of Multiple-Dependent Claims						\$ 260.00
Total Additional Fee for this Amendment						\$1,316.00
<input type="checkbox"/> The following other fees are incurred by the accompanying papers. <input type="checkbox"/> Other: _____						
Please charge Deposit Account No. 01-0519 in the name of Amgen Inc. in the amount of \$2,246.00. A duplicate copy of this petition is attached.						
<input type="checkbox"/> If an additional extension of time is required, please consider this a petition therefore.						
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required by the accompanying papers, or credit any overpayment to Deposit Account No. 01-0519.						
Please Send Future Correspondence To: U.S. Patent Operations/DRC M/S 10-1-B AMGEN INC. Amgen Center 1840 De Havilland Drive Thousand Oaks, California 91320-1789				 Daniel R. Curry Attorney for Applicants Registration No.: 32,727 Phone: (805) 447-8102 Date: September 11, 1997		

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

September 11, 1997

Date


 Christina Gutierrez
 Signature